Oral GLP-1R agonist OHP2 drives astrocyte-neuron metabolic coupling, showing neuroprotective potential in Alzheimer's disease

Metabolic dysfunction is a critical, yet often overlooked, factor in the progression of Alzheimer's disease (AD), contributing significantly to neuronal degeneration and cognitive decline. Current therapeutic strategies for AD often fall short, failing to address the underlying metabolic imbalances effectively. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise due to their neuroprotective properties, but their clinical utility for AD is hampered by poor blood-brain barrier (BBB) penetration and the lack of effective oral formulations. This study addresses the gap by investigating a novel oral GLP-1R agonist designed to cross the BBB and modulate cerebral metabolism.

Researchers investigated OHP2, a novel oral GLP-1R agonist specifically engineered for blood-brain barrier permeability, as a potential therapeutic agent for Alzheimer's disease. The study focused on elucidating its mechanism of action, particularly its interaction with GLP-1R on astrocytes and the subsequent metabolic changes. The abstract did not specify the exact experimental model (e.g., specific cell lines, in vitro assays, or animal models), sample sizes, dosing regimens, or specific analytical techniques (Western blot, mass spectrometry) used to determine these effects. The primary objective was to demonstrate how OHP2 facilitates astrocyte-neuron metabolic coupling.

The study found that OHP2 primarily activates GLP-1R located on astrocytes, initiating a cascade of metabolic events. This activation significantly increased astrocyte aerobic glycolysis, leading to enhanced lactate release into the extracellular space. Neurons subsequently took up this astrocyte-derived lactate, which in turn elevated histone H3 lysine 9 lactylation (H3K9la). This H3K9la modification played a crucial role in facilitating lipid transport from neurons back to astrocytes, establishing a robust metabolic coupling. This continuous astrocyte-neuron metabolic exchange, sustained by OHP2, supports ongoing aerobic glycolysis and is proposed to alleviate metabolic disturbances characteristic of Alzheimer's disease. The H3K9la mechanism specifically links glucose and lipid metabolic cycles, demonstrating a novel pathway for GLP-1R action in the brain.

OHP2 activates astrocyte GLP-1R, driving lactate release and subsequent neuronal H3K9la, which facilitates neuron-to-astrocyte lipid transfer, establishing a metabolic coupling crucial for AD remission.